Moderna inks fill-finish pact with Spain's Rovi for 'hundreds of millions' of COVID-19 shot doses

Syringe injection vaccine needle
Moderna is hoping to build capacity for 1 billion doses of its COVID-19 vaccine per year. (Pixabay)

Moderna is on a steady march to market with its mRNA-based COVID-19 vaccine, and the company is snapping up manufacturing capacity along the way. After inking one fill-finish deal with major CDMO Catalent last month, Moderna has now put its name to a second pact. 

Moderna signed a deal with Spain's Laboratorios Farmacéuticos Rovi for fill-finish duties on "hundreds of millions" of the Massachusetts-based vaccine maker's mRNA COVID-19 shot candidate, the partners said Thursday. 

Rovi will tackle the finishing work for Moderna's vaccine at its Madrid facility after purchasing a new production line and equipment for compounding, filling, automatic visual inspection and labeling, according to a joint release. 

Sept. 15-17,2020

Cytiva Virtual Event: Tapas & Tech Talks Copy - Strategies for robust and scalable

Strategies for robust and scalable processes: from research through late-stage trials
(with Cytiva and IQVIA)

Rovi expects to start the work in early 2021 and will hire additional staff to take on the increased manufacturing load. The partners did not disclose financial terms for the deal. 

RELATED: Moderna aims for light-speed COVID-19 shot rollout with Catalent fill-finish deal

Suggested Articles

WuXi Biologics has tapped its former Chinese facility head as CEO of its still-in-the-works vaccines CDMO unit in Ireland.

After a slow start, Teva's Ajovy launch is improving following the FDA approval for an autoinjector.

Lupin pulled one lot of lisinopril after finding the wrong tablets in some bottles. Sun Pharma yanked clonazepam bottles on contamination fears.